Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA ApprovalPulmonary arterial hypertension (PAH) is a rare form of hypertension affecting lung arteries, leading to heart problems.FDA approved a new Merck drug, Winrevair (sotatercept), which targets an underlying cause of PAH and helps alleviate symptoms.